# Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants

> **NCT02833831** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 103 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ALS-008176
- **DRUG:** Placebo
- **DRUG:** Moxifloxacin

## Key facts

- **NCT ID:** NCT02833831
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-02
- **Primary completion:** 2017-02-17
- **Final completion:** 2017-02-24
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02833831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02833831, "Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02833831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*